Continuous ghrelin infusion attenuates the postoperative inflammatory response in patients with esophageal cancer

What Was Tested

This clinical trial, phase i paper looks at Ghrelin.

The aim of this study was to clarify whether ghrelin infusion is useful for suppressing inflammatory responses after esophagectomy.

Who Took Part

According to the abstract, 20 patients were involved.

A phase I study of ghrelin administration after esophagectomy was performed in 20 patients with esophageal cancer.

The anti-inflammatory effect of ghrelin was compared with 20 consecutive patients who did not receive ghrelin infusion.

How the Study Was Run

The timeline in the abstract includes 10 days.

Additionally, 10 patients with intermittent infusion for 10 days were compared with 10 patients with continuous infusion for 5 days.

The primary endpoint was the duration of systemic inflammatory response syndrome (SIRS).

Secondary endpoints included postoperative complications, serum C-reactive protein (CRP), interleukin-6 (IL-6), and growth hormone (GH) levels.

What Was Measured

PubMed files the paper under topics including Esophageal Neoplasms, Esophagectomy, Ghrelin, Postoperative Period and Systemic Inflammatory Response Syndrome.

Author keywords: Esophageal cancer and Growth hormone.

What This Means in Plain Language

This is a clinical trial, phase i of Ghrelin in 20 patients over 10 days.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Esophagus : official journal of the Japan Esophageal Society), a journal based in Japan.

More context: the Ghrelin compound page, all human trials.